Small patient populations represent a huge market opportunity. Orphan drugs represent one of the pharma industry's hottest growth markets, and new figures from Thomson Reuters underscores that the blistering rise in revenue will drive the development of the next generation of experimental products.
Now that Amylin and Human Genome Sciences have completed their buyout deals, the biotech industry is virtually humming with gossip about the next sizable buyout.
The Telegraph in the U.K. is reporting that the market buzz indicates that GSK is in talks with BioMarin, the rare disease drug outfit that has been snapping up programs in recent months.
With the rare disease drug field as crowded as ever, BioMarin Pharmaceutical ( $BMRN ) is in the market to snap up smaller developers of the treatments to build on the company's established position in
One of the big trends in drug development over the past three years has been the growing popularity of new treatments for rare diseases. And if you read through Bloomberg's lengthy feature on Novato,
Now that Genzyme is destined to become the center of Sanofi-Aventis' new division for drugs that treat rare diseases, the internal focus at the company has turned to whose jobs and which development
With investors cashing in on Genzyme's buyout investors are scouring the biotech landscape for new developers to back in hopes of making similar returns. Dow Jones polled a list of analysts, and some
Continuing its year-long buying spree, BioMarin Pharmaceutical has agreed to pay up to $115 million to snare ZyStor Therapeutics and its preclinical candidate for Pompe disease. BioMarin is slapping
TheStreet's top biotech stock ace, Adam Feuerstein, has culled through a mountain of releases and reports to come up with the 10 most closely-watched trial announcements expected in the second half
When BioMarin board member Joseph Klein opted to step down from his position with the company, he presented a laundry list of disagreements in his resignation letter. But the one that's caught the